53292-89-0

Basic information

• Product Name: BOC-1,4-TRANS-ACHC-OH
• Synonyms: RARECHEM AR PA 0013;TRANS-4-TERT-BUTOXYCARBONYLAMINOCYCLOHEXANECARBOXYLIC ACID;TRANS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;TRANS-1-(T-BUTYLOXYCARBONYLAMINO)CYCLOHEXYL-4-CARBOXYLIC ACID;TRANS-1-(TERT-BUTYLOXYCARBONYL-AMINO)-CYCLOHEXYL-4-CARBOXYLIC ACID;BOC-1,4-TRANS-ACHC-OH;BOC-TRANS-1,4-AMINOCYCLOHEXANE CARBOXYLIC ACID;BOC-TRANS-4-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID
• CAS NO: 53292-89-0
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: Alicyclic Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 53292-89-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 181.0 to 185.0 °C
• Boiling Point: 396.7 °C at 760 mmHg
• Flash Point: 193.7 °C
• Appearance: White/Powder
• Density: 1.13 g/cm³
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform, Methanol (Slightly)
• PKA: 4.76±0.10(Predicted)
• BRN: 7641071
• CAS DataBase Reference: BOC-1,4-TRANS-ACHC-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-1,4-TRANS-ACHC-OH(53292-89-0)
• EPA Substance Registry System: BOC-1,4-TRANS-ACHC-OH(53292-89-0)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 53292-89-0(Hazardous Substances Data)

Usage

Description

BOC-1,4-TRANS-ACHC-OH, also known as Boc-trans-4-aminocyclohexanecarboxylic acid, is a white solid reagent used in the synthesis of N-myristoyltransferase and CD38 inhibitors. It plays a crucial role in the development of pharmaceutical compounds targeting these enzymes, which are involved in various cellular processes and have potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
BOC-1,4-TRANS-ACHC-OH is used as a reagent for the synthesis of N-myristoyltransferase and CD38 inhibitors for their potential therapeutic applications in various diseases.
Used in Research and Development:
BOC-1,4-TRANS-ACHC-OH is used as a key compound in the research and development of novel inhibitors targeting N-myristoyltransferase and CD38 enzymes, contributing to the advancement of medical science and the discovery of new treatments for various conditions.
Used in Drug Synthesis:
BOC-1,4-TRANS-ACHC-OH is used as an essential building block in the synthesis of drugs that modulate the activity of N-myristoyltransferase and CD38, which can have implications in the treatment of various diseases and disorders related to these enzymes.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9-

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 
• 150-13-0 4-amino-benzoic acid 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 

Downstream Products

• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 400898-94-4 trans-(4-formylcyclohexyl)methylcarbamic acid tert-butyl ester 
• 400899-08-3 tert-butyl ((1r,4r)-4-(hydroxymethyl)cyclohexyl)(methyl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 400899-12-9 methyl-[4-(3-oxo-propyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 400899-11-8 [4-(3-hydroxy-propyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-10-7 3-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-propionic acid ethyl ester 
• 400899-16-3 [4-(5-hydroxy-pentyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-17-4 methanesulfonic acid 5-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-pentyl ester 
• 878395-72-3 4-amino-cyclohexanecarboxylic acid [2-(cyclopentanecarbonyl-amino)-benzothiazol-6-yl]-amide 
• 216957-26-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)piperazine 
• 216957-35-6 ethyl 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)-2-piperazinecarboxylate 
• 757171-98-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(5-chloro-2H-benzopyran-3-sulfonyl)piperazine 
• 944404-27-7 [trans-4-(4-isopropyl-piperazine-1-carbonyl)-cyclohexyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Preparation method of trans 4 - (tert-butyloxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof

The invention provides a preparation method of trans 4 - (tert-butyloxycarbonylamino) cyclohexanecarboxylic acid and an intermediate thereof. The preparation method is characterized by comprising the following steps of 4 - oxocyclohexane carboxylic ester and chiral ligand reagent tert-butyl sulfinamide as a raw material, reducing amination to obtain trans -4 -tert-butyl sulfinyl sulfenamide cyclohexane carboxylic acid ester by virtue of chiral ligand reagent tert-butyl sulfinamide and 4 - 95% -oxocyclohexane carboxylic ester, and is stable in basic conditions and easy to leave under an acidic condition. Reaction conditions are mild, operation is simple and convenient, yield is high, and industrial production is easy.

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat